IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid derived suppressor cells<sup><a href="#FN1" rid="FN1" class=" fn">1</a></sup>
INTRODUCTION
Immune responses have paradoxical roles in tumor development (1, 2). On one side, immune responses play a key role in immune-surveillance for prevention of tumor development. Numerous studies indicate that anti-tumor immune responses are able to prevent and eliminate tumors. On the other side, however, immune responses, especially in a form of chronic inflammation, promote tumor development in many cases (3, 4). A prominent feature of tumor promoting immune responses is the increased number of myeloid derived suppressor cells (MDSC) in the blood, spleen and bone marrow and abundant infiltration of MDSC at the tumor site (5–8). Heavy infiltration of MDSC has been considered as a major cause for immunosuppression at tumor sites (5, 8, 9). MDSC are considered as an immature form of myeloid cells which are mostly identified as CD11b and Gr-1 double positive cells in mice (7, 10). MDSC are able to suppress anti-tumor immune responses and promote tumor growth (5, 8). Recent studies have shown that MDSC are composed of two subpopulations, which suppress T cell responses by different mechanisms (11, 12). Inflammatory cytokines and tumor derived mediators have been reported to regulate MDSC (5–8). However, mechanisms for the development and function of MDSC remain to be fully elucidated.
IL-17 is an inflammatory cytokine secreted by CD4 Th17 and CD8 Tc17 cells (13–17). Six IL-17 family members (IL-17A-F) have been described and the prototype member of the family is IL-17A, often termed IL-17 in literature. The receptor for IL-17A and IL-17F is IL-17RA, generally termed IL-17R which is expressed ubiquitously (14). IL-17 plays an important role in the regulation of leukocyte migration in inflammatory reactions and a defect in IL-17R decreases the expression of cytokines, chemokines and reduces the infiltration of inflammatory cells, especially neutrophils (18–23). The role of IL-17 in inflammatory and autoimmune diseases has been extensively studied (13, 15, 16, 24).
Although IL-17 producing cells are detected in cancer patients and tumor bearing mice (25–28), the role of IL-17 in tumor development is controversial (22, 29–35). Recent reports indicate that tumor growth is increased in IL-17−/− mice and that the mechanism is associated with IFN-γ producing NK and T cells (32, 35). It implicates that IL-17 mediated responses are protective against tumor development. However, another recent report shows that tumor growth is suppressed in IL-17−/− and IL-17/IFN-γ double knockout mice (31). A mechanism is that IL-17 induces the production of IL-6 by tumor cells, which in turn promotes tumor growth in a Stat-3 dependent pathway. Interestingly, the report shows that the production of IFN-γ by tumor infiltrating T cells from IL-17−/− mice is increased (31). Although IFN-γ plays a role in the regulation of anti-tumor immune responses (36–38), CTL activity of tumor specific T cells is an important mechanism for T cell mediated tumor rejection. It is not examined whether IL-17 regulates the CTL activity of tumor specific CD8 T cells. Moreover, it is largely unknown whether IL-17 mediated effects on innate immune cells, such as MDSC, play a role in tumor immune responses.
It is often observed that T cells from tumor patients retain the ability to respond to tumor antigens. However, immune responses in peripherals are not correlated with tumor rejection (39–41). Mechanisms for immunosuppression include failure of immune T cell infiltration into tumors and presence of Treg cells and immune suppressive myeloid cells at tumor sites (8, 42–44). The infiltration of immune T cells in tumors is associated with good prognosis (45) whereas infiltration of MDSC is associated with poor prognosis (5, 8). Although it is well documented that IL-17 is an important cytokine for the regulation of leukocyte infiltration in inflammatory tissues (18–22), it remains to be examined whether IL-17 plays a role in the regulation of immune responses at tumor sites.
In the current study, we examined the effect of endogenous IL-17 on the growth of tumors in mice that were deficient in IL-17 receptor A (IL-17R−/−). Additionally, anti-IL-17 antibodies and exogenous IL-17 cytokine were applied to further confirm the effect of IL-17 on tumor development. We examined IL-17 mediated effects on the infiltration of tumor specific T cells and myeloid cells in tumors and determined the role of IL-17 in the development of MDSC in tumor bearing mice. Our findings indicate that IL-17 promotes tumor development through the induction of tumor promoting responses at tumor sites and enhancement of MDSC.
MATERIALS AND METHODS
Mice
IL-17R−/− mice on C57BL/6 background were provided by Amgen. IFN-γR−/− (C57BL/6 background) and wild type C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). IL-17R−/− mice were cross-bred to IFN-γR−/− mice to generate double knockout mice in our laboratory. The gene phenotype was routinely confirmed by PCR using specific primers. All animal procedures were performed according to NIH guidelines and the protocols were approved by the Institute Animal Care and Use Committee of the University of Alabama at Birmingham.
Transplanted tumor models: Protocols for inoculation and measurement of tumors in transplanted tumor models were reported previously (46). Mouse lymphoma cell line EL4, E.G7-OVA (EL4 transfected with OVA gene), prostate tumor cell line Tramp-C2 and melanoma cell line B16-F10 were purchased from the ATCC. Tumor cells were injected subcutaneously in mice and tumor growth was monitored every 3 days. Tumor sizes were calculated with the formula: Tumor Size = L × S × H × π/6 (L: long diameter, S: short diameter, H: height).
To examine the effect of IL-17 on tumor growth, mice were treated intravenously with adenovirus encoding GFP (Ad-GFP) or mouse IL-17A (Ad-IL-17) (10 pfu/mouse) (kindly provided by Dr. Jay K. Kolls, University of Pittsburgh) as described (47). Two days later, the mice were inoculated with E.G7-OVA tumor cells.
To examine the effect of neutralizing IL-17 on tumor growth, mice were inoculated subcutaneously with E.G7-OVA tumor cells and treated intraperitoneally with normal rat IgG or a rat anti-mouse IL-17 monoclonal antibody (100µg/mouse) (TC11-18H10, anti-IL-17A, Southern Biotechnology Inc., Birmingham, AL) on day 0 (the day of tumor inoculation), 1, 6, 10, and 14.
To examine effects of MDSC on tumor growth, MDSC were purified from spleens of tumor bearing mice by using anti-CD11b antibody coupled magnet beads according to the manufacturer’s instructions (MACS system, Miltenyi Biotec, Auburn, CA). The purity of the cells was >90% as assessed by flow cytometry. The cells were co-injected (5×10/mouse) subcutaneously with E.G7-OVA tumor cells (4×10/mouse) in wild type mice. In experiments using B16 tumors, MDSC (2×10/mouse) were co-injected subcutaneously with B16 melanoma cells (1×10/mouse) in wild type mice. Tumor growth was monitored.
Immunohistochemical staining of tissues
Immunohistochemical staining of tissue sections was described in our previous studies (17). Frozen tissue sections (5 µM) were made for staining of CD8 positive cells. Paraffin embedded sections (6 µM) were made for staining of PCNA positive cells. The antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and BD-Biosciences (San Diego, CA). Pictures were taken microscopically (10× objective) with a digital camera (Olympus). Positive cells were counted in 10 fields of each group. Average numbers of positive cells per field were calculated and analyzed statistically.
Flow cytometry analysis
To examine tumor infiltrating cells, tumor tissues were cut into small pieces and digested in RPMI containing collagenase-D 2mg/ml (Sigma), Dnase I 50ug/ml (Sigma), and 10%FCS. To detect MDSC, cell suspensions of tumors and spleens or blood leukocytes were stained with Alexa488 labeled CD11b and allophycocyanin labeled Gr-1 antibodies (BD-Biosciences). The percent of cells which expressed a high level of both CD11b and Gr-1 was analyzed in a flow cytometer (FACScaliber, Becton-Dickinson) as described (17). To detect tumor antigen OVA specific CD8 T cells in tumors, tumor cell suspensions were stained with Alexa488 labeled anti-CD8 antibody and phycoerythrin labeled OVA/MHC class-I tetramers which bind to OVA specific CD8 T cells (iTAg MHC Tetramer, Beckman Coulter). CD8 T cells were gated and the percent of the tetramer positive cells was analyzed by flow cytometry.
Assays for T cell functions
CD8 T cells from spleens of tumor bearing mice were purified by using the MACS system according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). In our hands, this procedure results in >90% selection of CD8 T cells. Bone marrow derived dendritic cells (BM-DC) were generated from bone marrows of C57BL/6 as described in our previous report (17) and pulsed with OVA (100 µg/ml) for overnight.
To detect cytokine production by tumor specific T cells, spleen cells of tumor bearing mice were stimulated with OVA-pulsed BM-DC for 4 days (2 × 10 T cells plus 2 × 10 DC/ml). Our preliminary data showed that the stimulation of T cells with OVA-pulsed BM-DC for 4 days induced optimal levels of cytokine producing cells and cytokines in cultures compared to cultures for 1, 2 or 3 days (data not shown). Concentrations of cytokines in supernatants were measured by cytokine specific ELISA as described in our previous studies (23). To detect cytokine producing T cells, cells were harvested 4 days after cultures and stimulated with PMA (50ng/ml) and ionomycin (500ng/ml) in the present of Golgi Stop (BD Pharmingen) for 4–6 hrs. Intracellular cytokines were stained and cytokine producing cells were analyzed in a flow cytometer as described in our previous report (17).
To examine the CTL activity of tumor specific CD8 T cells, CD8 T cells were purified from spleens of E.G7-OVA tumor bearing mice and stimulated in vitro with OVA-pulsed BM-DC for 5 days (2 × 10 T cells plus 2 × 10 DC/ml). E.G7-OVA tumor cells were labeled with 5 µM CFSE and used as antigen specific target cells. EL4 cells were labeled with 0.5 µM CFSE and used as control cells. E.G7-OVA and EL4 cells were mixed at 1:1 ratio and used as target cells. The CD8 T cells which were harvested after the in vitro stimulation were incubated with mixed target cells (E.G7-OVA/EL4) (1× 10/well) at ratios of 100:1, 50:1, 25:1 and 0:1 (control) for 4 hours. Each sample was quadruplicated. The specific lysis of target cells was calculated with the formula as reported (48): %specific cytotoxicity = 100 × [1-(E.G7-OVA/EL4)experimental/(E.G7-OVA/EL4)control].
To examine the effect of MDSC on T cell activation, CD4 T cells were purified from naïve wild type mice by the MACS system and labeled with a fluorescence dye Carboxyfluorescein succinimidyl ester (CFSE, Molecular Probe) at 5 µM for 20 min. The CFSE labeled CD4 T cells were then placed in cultures with purified MDSC from wild type or IL-17R−/− tumor bearing mice (2 × 10 T cells to 1 × 10 MDSC/ml). CD11b+ cells from tumor free wild type mice served as controls. The cultures were stimulated with plate-bound anti-CD3 (20 µg, BD Pharmingen) and anti-CD28 (20 µg/ml, BD Pharmingen) antibodies for 4 days. T cells that were not stimulated with the antibodies served as negative controls. The division of CD4 T cells was analyzed by flow cytometry.
TUNEL assay
Apoptotic cells were detected by TUNEL assay as described in our previous report (46). Briefly, tumor samples were fixed in 10% formalin and sections (5 µm) were made. TUNEL assay was performed using a commercial apoptosis detection kit according to the manufacturer’s instructions (Promega, Madison, WI). Sections were counterstained with DAPI and photographed microscopically with a 10× objective. The number of apoptotic cells was counted and results from 10 fields of each group were calculated for statistical analysis.
Real time quantitative RT-PCR
The expression of mRNA was quantified by real time RT-PCR as described in our previous report (23). Briefly, MDSC were purified from spleen of tumor bearing mice by using the MACS system and stimulated with LPS (5 µg/ml) for overnight. Total RNA was isolated from the cells by using TRIzol Reagent according to the manufacture’s instructions (GibcoBRL). Real time TR-PCR was performed with iQ SYBRO Green Supermix Kit in a MyiQ real time qPCR system according to the manufacture’s instructions (Bio-Rad). The expression level of cytokines was normalized to the house-keeping gene GAPDH in each sample. The sequences for primers were: Arginase-1: forward, 5’-ATGGAAGAGACCTTCAGCTAC-3’, reverse, 5’-GCTGTCTTCCCAAGAGTTGGG-3’; S100A8: forward, 5’-ACAATGCCGTCTGAACTGG-3’, reverse, 5’-CTCTGCTACTCCTTGTGGCTGTCT-3’; S100A9: forward, 5’- TCATCGACACCTTCCATCAA-3’, reverse, 5’- GATCAACTTTGCCATCAGCA-3’; MMP9: forward, 5’- CATCGAACTTCGACACTGAC-3’, reverse, 5’- AGCCACGACCATACAGATAC-3’; GApDH: forward, 5 ’-AATGGTGAAGGTCGGTGTGAAC-3’, reverse, 5’-GAAGATGGTGATGGGCTTCC.
Statistical analysis
All data are presented as means ± SEM. The two tailed Student's t-test was applied for statistical analysis with P<0.05 being considered statistically significant.
Mice
IL-17R−/− mice on C57BL/6 background were provided by Amgen. IFN-γR−/− (C57BL/6 background) and wild type C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, Maine). IL-17R−/− mice were cross-bred to IFN-γR−/− mice to generate double knockout mice in our laboratory. The gene phenotype was routinely confirmed by PCR using specific primers. All animal procedures were performed according to NIH guidelines and the protocols were approved by the Institute Animal Care and Use Committee of the University of Alabama at Birmingham.
Transplanted tumor models: Protocols for inoculation and measurement of tumors in transplanted tumor models were reported previously (46). Mouse lymphoma cell line EL4, E.G7-OVA (EL4 transfected with OVA gene), prostate tumor cell line Tramp-C2 and melanoma cell line B16-F10 were purchased from the ATCC. Tumor cells were injected subcutaneously in mice and tumor growth was monitored every 3 days. Tumor sizes were calculated with the formula: Tumor Size = L × S × H × π/6 (L: long diameter, S: short diameter, H: height).
To examine the effect of IL-17 on tumor growth, mice were treated intravenously with adenovirus encoding GFP (Ad-GFP) or mouse IL-17A (Ad-IL-17) (10 pfu/mouse) (kindly provided by Dr. Jay K. Kolls, University of Pittsburgh) as described (47). Two days later, the mice were inoculated with E.G7-OVA tumor cells.
To examine the effect of neutralizing IL-17 on tumor growth, mice were inoculated subcutaneously with E.G7-OVA tumor cells and treated intraperitoneally with normal rat IgG or a rat anti-mouse IL-17 monoclonal antibody (100µg/mouse) (TC11-18H10, anti-IL-17A, Southern Biotechnology Inc., Birmingham, AL) on day 0 (the day of tumor inoculation), 1, 6, 10, and 14.
To examine effects of MDSC on tumor growth, MDSC were purified from spleens of tumor bearing mice by using anti-CD11b antibody coupled magnet beads according to the manufacturer’s instructions (MACS system, Miltenyi Biotec, Auburn, CA). The purity of the cells was >90% as assessed by flow cytometry. The cells were co-injected (5×10/mouse) subcutaneously with E.G7-OVA tumor cells (4×10/mouse) in wild type mice. In experiments using B16 tumors, MDSC (2×10/mouse) were co-injected subcutaneously with B16 melanoma cells (1×10/mouse) in wild type mice. Tumor growth was monitored.
Immunohistochemical staining of tissues
Immunohistochemical staining of tissue sections was described in our previous studies (17). Frozen tissue sections (5 µM) were made for staining of CD8 positive cells. Paraffin embedded sections (6 µM) were made for staining of PCNA positive cells. The antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and BD-Biosciences (San Diego, CA). Pictures were taken microscopically (10× objective) with a digital camera (Olympus). Positive cells were counted in 10 fields of each group. Average numbers of positive cells per field were calculated and analyzed statistically.
Flow cytometry analysis
To examine tumor infiltrating cells, tumor tissues were cut into small pieces and digested in RPMI containing collagenase-D 2mg/ml (Sigma), Dnase I 50ug/ml (Sigma), and 10%FCS. To detect MDSC, cell suspensions of tumors and spleens or blood leukocytes were stained with Alexa488 labeled CD11b and allophycocyanin labeled Gr-1 antibodies (BD-Biosciences). The percent of cells which expressed a high level of both CD11b and Gr-1 was analyzed in a flow cytometer (FACScaliber, Becton-Dickinson) as described (17). To detect tumor antigen OVA specific CD8 T cells in tumors, tumor cell suspensions were stained with Alexa488 labeled anti-CD8 antibody and phycoerythrin labeled OVA/MHC class-I tetramers which bind to OVA specific CD8 T cells (iTAg MHC Tetramer, Beckman Coulter). CD8 T cells were gated and the percent of the tetramer positive cells was analyzed by flow cytometry.
Assays for T cell functions
CD8 T cells from spleens of tumor bearing mice were purified by using the MACS system according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). In our hands, this procedure results in >90% selection of CD8 T cells. Bone marrow derived dendritic cells (BM-DC) were generated from bone marrows of C57BL/6 as described in our previous report (17) and pulsed with OVA (100 µg/ml) for overnight.
To detect cytokine production by tumor specific T cells, spleen cells of tumor bearing mice were stimulated with OVA-pulsed BM-DC for 4 days (2 × 10 T cells plus 2 × 10 DC/ml). Our preliminary data showed that the stimulation of T cells with OVA-pulsed BM-DC for 4 days induced optimal levels of cytokine producing cells and cytokines in cultures compared to cultures for 1, 2 or 3 days (data not shown). Concentrations of cytokines in supernatants were measured by cytokine specific ELISA as described in our previous studies (23). To detect cytokine producing T cells, cells were harvested 4 days after cultures and stimulated with PMA (50ng/ml) and ionomycin (500ng/ml) in the present of Golgi Stop (BD Pharmingen) for 4–6 hrs. Intracellular cytokines were stained and cytokine producing cells were analyzed in a flow cytometer as described in our previous report (17).
To examine the CTL activity of tumor specific CD8 T cells, CD8 T cells were purified from spleens of E.G7-OVA tumor bearing mice and stimulated in vitro with OVA-pulsed BM-DC for 5 days (2 × 10 T cells plus 2 × 10 DC/ml). E.G7-OVA tumor cells were labeled with 5 µM CFSE and used as antigen specific target cells. EL4 cells were labeled with 0.5 µM CFSE and used as control cells. E.G7-OVA and EL4 cells were mixed at 1:1 ratio and used as target cells. The CD8 T cells which were harvested after the in vitro stimulation were incubated with mixed target cells (E.G7-OVA/EL4) (1× 10/well) at ratios of 100:1, 50:1, 25:1 and 0:1 (control) for 4 hours. Each sample was quadruplicated. The specific lysis of target cells was calculated with the formula as reported (48): %specific cytotoxicity = 100 × [1-(E.G7-OVA/EL4)experimental/(E.G7-OVA/EL4)control].
To examine the effect of MDSC on T cell activation, CD4 T cells were purified from naïve wild type mice by the MACS system and labeled with a fluorescence dye Carboxyfluorescein succinimidyl ester (CFSE, Molecular Probe) at 5 µM for 20 min. The CFSE labeled CD4 T cells were then placed in cultures with purified MDSC from wild type or IL-17R−/− tumor bearing mice (2 × 10 T cells to 1 × 10 MDSC/ml). CD11b+ cells from tumor free wild type mice served as controls. The cultures were stimulated with plate-bound anti-CD3 (20 µg, BD Pharmingen) and anti-CD28 (20 µg/ml, BD Pharmingen) antibodies for 4 days. T cells that were not stimulated with the antibodies served as negative controls. The division of CD4 T cells was analyzed by flow cytometry.
TUNEL assay
Apoptotic cells were detected by TUNEL assay as described in our previous report (46). Briefly, tumor samples were fixed in 10% formalin and sections (5 µm) were made. TUNEL assay was performed using a commercial apoptosis detection kit according to the manufacturer’s instructions (Promega, Madison, WI). Sections were counterstained with DAPI and photographed microscopically with a 10× objective. The number of apoptotic cells was counted and results from 10 fields of each group were calculated for statistical analysis.
Real time quantitative RT-PCR
The expression of mRNA was quantified by real time RT-PCR as described in our previous report (23). Briefly, MDSC were purified from spleen of tumor bearing mice by using the MACS system and stimulated with LPS (5 µg/ml) for overnight. Total RNA was isolated from the cells by using TRIzol Reagent according to the manufacture’s instructions (GibcoBRL). Real time TR-PCR was performed with iQ SYBRO Green Supermix Kit in a MyiQ real time qPCR system according to the manufacture’s instructions (Bio-Rad). The expression level of cytokines was normalized to the house-keeping gene GAPDH in each sample. The sequences for primers were: Arginase-1: forward, 5’-ATGGAAGAGACCTTCAGCTAC-3’, reverse, 5’-GCTGTCTTCCCAAGAGTTGGG-3’; S100A8: forward, 5’-ACAATGCCGTCTGAACTGG-3’, reverse, 5’-CTCTGCTACTCCTTGTGGCTGTCT-3’; S100A9: forward, 5’- TCATCGACACCTTCCATCAA-3’, reverse, 5’- GATCAACTTTGCCATCAGCA-3’; MMP9: forward, 5’- CATCGAACTTCGACACTGAC-3’, reverse, 5’- AGCCACGACCATACAGATAC-3’; GApDH: forward, 5 ’-AATGGTGAAGGTCGGTGTGAAC-3’, reverse, 5’-GAAGATGGTGATGGGCTTCC.
Statistical analysis
All data are presented as means ± SEM. The two tailed Student's t-test was applied for statistical analysis with P<0.05 being considered statistically significant.
RESULTS
Tumor growth is inhibited in IL-17R−/− mice
The effect of IL-17 on tumor growth is controversial (22, 30–32). It is not yet reported whether a defect in IL-17R affects tumor growth. To examine it, wild type mice and IL-17R−/− mice which were deficient in response to IL-17A and IL-17F were inoculated subcutaneously with various types of tumor cell lines and tumor growth was monitored. Results showed that the growth of the lymphoma cell line EL4 (2 × 10/mouse), melanoma cell line B16-F10 (1 × 10/mouse), and prostate tumor cell line Tramp-C2 (2 × 10/mouse) was significantly inhibited in IL-17R−/− mice compared to wild type mice (Fig. 1a, b and c).
Literature and our previous studies indicate that IL-17 stimulates IFN-γ production whereas IFN-γ inhibits IL-17 production by T cells (23, 49, 50). However, it is unknown whether the interaction of IL-17 and IFN-γ affects tumor development. To examine the role of IFN-γ in IL-17 mediated regulation of tumor development, we have generated IL-17R/IFN-γR double knockout mice. Mice were inoculated subcutaneously with a high-immunogenic cell line E.G7-OVA (4 × 10 cells/mouse). Results showed that tumor growth was increased in IFN-γR−/− mice whereas decreased in IL-17R−/− mice compared to wild type mice (Fig. 1d). In the double knockout mice that were deficient in both IL-17R and IFN-γR, tumor growth was significantly reduced compared to wild type mice (Fig. 1d). This suggests that the IL-17R deficiency inhibited the growth of high-immunogenic tumors. Moreover, although the deficiency in IFN-γR signals enhanced tumor growth, the IL-17R deficiency reversed the susceptibility of IFN-γR−/− mice to tumor development. In order to examine immunological mechanisms for IL-17 mediated effects on tumor growth, E.G7-OVA tumor cells were applied in all following experiments
To further determine whether IL-17 promoted tumor growth, wild type mice were injected intravenously with adenovirus encoding mouse IL-17 (Ad-IL-17) or GFP (Ad-GFP) (10 pfu/mouse) and then inoculated with E.G7-OVA tumor cells. Results showed that the treatment with Ad-IL-17 significantly increased tumor growth compared to control mice that were treated with Ad-GFP or left untreated (Fig. 2a). In contrast, treatment of wild type mice with a neutralizing anti-IL-17 antibody significantly inhibited the growth of E.G7-OVA tumors compared to controls that were treated with rat IgG (Fig. 2b).
Analysis of IL-17 mediated effects on tumors
To examine effects of the IL-17R deficiency on tumors, tumor tissues from tumor bearing mice were collected and subjected to analysis. Results showed that the number of proliferating cells in tumors, which were stained with anti-proliferating cell nuclear antigen (PCNA) antibody, was significantly reduced in IL-17R−/− mice compared to wild type animals (Fig. 3a). In contrast, the number of apoptotic cells which were detected by TUNEL assay was significantly increased in IL-17R−/− tumors (Fig. 3b). These results suggest that the deficiency in IL-17R inhibits tumor cell proliferation and enhances apoptosis.
The immunity at tumor sites is important for the fate of tumors and the infiltration of T cells is closely associated with prognosis (5, 8, 9, 45). We found that the infiltration of CD8 T cells in tumors, which are major effector cells for tumor rejection, was significantly increased in IL-17R−/− mice (Fig. 3c). The infiltration of CD8 T cells in tumors of IFN-γR−/− was hardly affected whereas it was significantly increased in the double knockout mice that were deficient in both IL-17R and IFN-γR. The inhibitory effect of IL-17 on CD8 T cell infiltration in tumors was supported by further experiments showing that the treatment of mice with Ad-IL-17 reduced the infiltration of CD8 T cells in tumors (Fig. 3d). The effect of IL-17 on T cell infiltration appeared to be specific for CD8 T cells since no significant difference was found in CD4 T cell infiltration in tumors of wild type and IL-17R−/− mice (data not shown).
IL-17 mediated effects on tumor specific T cells
Based on the increased infiltration of CD8 T cells in tumors, we further characterized tumor infiltrating CD8 T cells. Results showed that the majority of tumor infiltrating CD8 T cells bound to OVA/MHC class-I tetramers (>70%) (Fig. 4a). There was not a remarkable difference in the percent of tumor specific CD8 T cells between wild type and IL-17R−/− mice although the infiltration of CD8 T cells was significantly increased in IL-17R−/− mice compared to wild type animals (Fig. 4b). Further analysis of tumor infiltrating CD8 T cells did not show a significant change in the expression of CTL related molecules perforin, Fas-L, and granzyme B between wild type and IL-17R−/− tumor bearing mice (data not shown).
To examine whether the IL-17R deficiency had an effect on T cell function, spleen cells of E.G7-OVA tumor bearing wild type and IL-17R−/− mice were collected and stimulated with OVA-pulsed BM-DC for 4 days. Results showed that CD4 and CD8 T cells that produced IFN-γ were reduced whereas IL-17 producing CD4 T cells were increased (Fig. 5a). Furthermore, ELISA assays showed that IL-17 was increased whereas IFN-γ was reduced in culture supernatants of IL-17R−/− T cells compared to those of wild type T cells (Fig. 5b). However, there was not a significant difference in T cell numbers between wild type and IL-17R−/− mice (data not shown), a result consistent with previous reports (23, 51),.
To determine whether the IL-17R−/− deficiency affected the CTL activity of CD8 T cells, CD8 T cells were purified from spleens of E.G7-OVA tumor bearing mice and stimulated with OVA-pulsed BM-DC for 5 days. CTL assays revealed that the CTL activity of CD8 T cells from IL-17R−/− and wild type tumor bearing mice was not significantly different (Fig. 5c). The experiment was repeated three times and similar results were observed. Collectively, the IL-17R−/− deficiency increased the infiltration of CD8 T cells in tumors, inhibited IFN-γ production by T cells but had little effect on the CTL activity of tumor specific CD8 T cells.
IL-17 is required for the development of myeloid derived suppressor cells
An increased number of myeloid derived suppressor cells (MDSC) in spleen, blood and tumors is a hallmark of major immunological abnormalities in cancer patients and tumor bearing animals (5–7). MDSC are considered as an immature form of myeloid cells which are mostly identified as CD11b and Gr-1 double positive cells in mice (7, 10). We found that the percent of CD11b/Gr-1 double positive MDSC in the spleen of IL-17R−/− tumor bearing mice was lower than that of wild type tumor bearing mice (Fig. 6a). The deficiency in IFN-γR had little effect on MDSC whereas MDSC in the double knockout mice that were deficient in both IL-17R and IFN-γR was reduced. Further analysis showed that MDSC in the spleen, blood and tumors of IL-17R−/− and the double knockout mice was significantly reduced compared to wild type controls (Fig. 6b).
In further experiments, results showed that spleens from tumor bearing mice that were treated with Ad-IL-17 (as described in Fig. 2a) contained a significantly higher level of MDSC than those from the mice that were treated with Ad-GFP or untreated control (Fig. 6c). In contrast, the number of MDSC in the spleen of tumor bearing mice which were treated with anti-IL-17 antibody (as described in Fig. 2b) was significantly reduced compared to controls that were treated with normal rat IgG (Fig. 6d). The deficiency in IFN-γR or IL-17R did not have a significant effect on the number of MDSC in tumor free naïve mice (data not shown).
IL-17 regulates the phenotype and function of myeloid derived suppressor cells
The tumor promoting function of MDSC is associated with increased activities of arginase-1 (Arg-1), MMP9, and S100A8/A9 (7, 10, 52). To examine mechanisms for IL-17 mediated effects on the phenotype of MDSC in tumor bearing mice, MDSC were purified from spleens of tumor bearing mice and stimulated with LPS in vitro for overnight. Our initial experiments showed a very low expression level of the molecules by freshly isolated MDSC without the LPS stimulation (data not shown). Results showed that MDSC from IL-17R−/− tumor bearing mice expressed lower levels of Arg-1, MMP9 and S100A8/A9 than those from wild type tumor bearing mice (Fig. 7). Furthermore, MDSC from Ad-IL-17 treated tumor bearing wild type mice expressed a higher level of the molecules than those from mice that were treated with Ad-GFP or left untreated (Fig. 7).
In experiments examining the tumor promoting function of MDSC, results showed that co-injection of MDSC purified from wild type E.G7-OVA tumor bearing mice significantly increased tumor growth whereas co-injection of MDSC from IL-17R−/− tumor bearing mice did not affect tumor growth compared to control mice that were not injected with MDSC (Fig. 8a). In contrast, MDSC from wild type tumor bearing mice that were treated with Ad-IL-17 promoted tumor growth to a significant greater extent than those from control wild type tumor bearing mice that were treated with Ad–GFP (Fig. 8b). Furthermore, similar results were also observed in mouse B16 melanoma model, which showed a reduced tumor promoting effect of MDSC from IL-17R−/− B16 tumor bearing mice compared to those from wild type counterparts (Fig. 8c). However, the tumor promoting activity of MDSC was dependent on the presence of tumors since co-injection of MDSC cells from naïve tumor free IL-17R−/− or wild type mice did not have a significant effect on tumor growth compared to control animals that were not injected with MDSC (Fig. 8d).
In experiments examining the immunosuppressive effect of MDSC, MDSC from wild type tumor bearing mice significantly inhibited the proliferation of CD4 T cells compared to control CD11b+ cells which were purified from tumor free mice (Fig. 8e). In contrast, MDSC from IL-17R−/− tumor bearing mice did not have an inhibitory effect on T cell proliferation compared to the control CD11b+ cells. These results indicate that MDSC from IL-17R−/− tumor bearing mice lack the functions in both tumor promotion and immunosuppression.
Tumor growth is inhibited in IL-17R−/− mice
The effect of IL-17 on tumor growth is controversial (22, 30–32). It is not yet reported whether a defect in IL-17R affects tumor growth. To examine it, wild type mice and IL-17R−/− mice which were deficient in response to IL-17A and IL-17F were inoculated subcutaneously with various types of tumor cell lines and tumor growth was monitored. Results showed that the growth of the lymphoma cell line EL4 (2 × 10/mouse), melanoma cell line B16-F10 (1 × 10/mouse), and prostate tumor cell line Tramp-C2 (2 × 10/mouse) was significantly inhibited in IL-17R−/− mice compared to wild type mice (Fig. 1a, b and c).
Literature and our previous studies indicate that IL-17 stimulates IFN-γ production whereas IFN-γ inhibits IL-17 production by T cells (23, 49, 50). However, it is unknown whether the interaction of IL-17 and IFN-γ affects tumor development. To examine the role of IFN-γ in IL-17 mediated regulation of tumor development, we have generated IL-17R/IFN-γR double knockout mice. Mice were inoculated subcutaneously with a high-immunogenic cell line E.G7-OVA (4 × 10 cells/mouse). Results showed that tumor growth was increased in IFN-γR−/− mice whereas decreased in IL-17R−/− mice compared to wild type mice (Fig. 1d). In the double knockout mice that were deficient in both IL-17R and IFN-γR, tumor growth was significantly reduced compared to wild type mice (Fig. 1d). This suggests that the IL-17R deficiency inhibited the growth of high-immunogenic tumors. Moreover, although the deficiency in IFN-γR signals enhanced tumor growth, the IL-17R deficiency reversed the susceptibility of IFN-γR−/− mice to tumor development. In order to examine immunological mechanisms for IL-17 mediated effects on tumor growth, E.G7-OVA tumor cells were applied in all following experiments
To further determine whether IL-17 promoted tumor growth, wild type mice were injected intravenously with adenovirus encoding mouse IL-17 (Ad-IL-17) or GFP (Ad-GFP) (10 pfu/mouse) and then inoculated with E.G7-OVA tumor cells. Results showed that the treatment with Ad-IL-17 significantly increased tumor growth compared to control mice that were treated with Ad-GFP or left untreated (Fig. 2a). In contrast, treatment of wild type mice with a neutralizing anti-IL-17 antibody significantly inhibited the growth of E.G7-OVA tumors compared to controls that were treated with rat IgG (Fig. 2b).
Analysis of IL-17 mediated effects on tumors
To examine effects of the IL-17R deficiency on tumors, tumor tissues from tumor bearing mice were collected and subjected to analysis. Results showed that the number of proliferating cells in tumors, which were stained with anti-proliferating cell nuclear antigen (PCNA) antibody, was significantly reduced in IL-17R−/− mice compared to wild type animals (Fig. 3a). In contrast, the number of apoptotic cells which were detected by TUNEL assay was significantly increased in IL-17R−/− tumors (Fig. 3b). These results suggest that the deficiency in IL-17R inhibits tumor cell proliferation and enhances apoptosis.
The immunity at tumor sites is important for the fate of tumors and the infiltration of T cells is closely associated with prognosis (5, 8, 9, 45). We found that the infiltration of CD8 T cells in tumors, which are major effector cells for tumor rejection, was significantly increased in IL-17R−/− mice (Fig. 3c). The infiltration of CD8 T cells in tumors of IFN-γR−/− was hardly affected whereas it was significantly increased in the double knockout mice that were deficient in both IL-17R and IFN-γR. The inhibitory effect of IL-17 on CD8 T cell infiltration in tumors was supported by further experiments showing that the treatment of mice with Ad-IL-17 reduced the infiltration of CD8 T cells in tumors (Fig. 3d). The effect of IL-17 on T cell infiltration appeared to be specific for CD8 T cells since no significant difference was found in CD4 T cell infiltration in tumors of wild type and IL-17R−/− mice (data not shown).
IL-17 mediated effects on tumor specific T cells
Based on the increased infiltration of CD8 T cells in tumors, we further characterized tumor infiltrating CD8 T cells. Results showed that the majority of tumor infiltrating CD8 T cells bound to OVA/MHC class-I tetramers (>70%) (Fig. 4a). There was not a remarkable difference in the percent of tumor specific CD8 T cells between wild type and IL-17R−/− mice although the infiltration of CD8 T cells was significantly increased in IL-17R−/− mice compared to wild type animals (Fig. 4b). Further analysis of tumor infiltrating CD8 T cells did not show a significant change in the expression of CTL related molecules perforin, Fas-L, and granzyme B between wild type and IL-17R−/− tumor bearing mice (data not shown).
To examine whether the IL-17R deficiency had an effect on T cell function, spleen cells of E.G7-OVA tumor bearing wild type and IL-17R−/− mice were collected and stimulated with OVA-pulsed BM-DC for 4 days. Results showed that CD4 and CD8 T cells that produced IFN-γ were reduced whereas IL-17 producing CD4 T cells were increased (Fig. 5a). Furthermore, ELISA assays showed that IL-17 was increased whereas IFN-γ was reduced in culture supernatants of IL-17R−/− T cells compared to those of wild type T cells (Fig. 5b). However, there was not a significant difference in T cell numbers between wild type and IL-17R−/− mice (data not shown), a result consistent with previous reports (23, 51),.
To determine whether the IL-17R−/− deficiency affected the CTL activity of CD8 T cells, CD8 T cells were purified from spleens of E.G7-OVA tumor bearing mice and stimulated with OVA-pulsed BM-DC for 5 days. CTL assays revealed that the CTL activity of CD8 T cells from IL-17R−/− and wild type tumor bearing mice was not significantly different (Fig. 5c). The experiment was repeated three times and similar results were observed. Collectively, the IL-17R−/− deficiency increased the infiltration of CD8 T cells in tumors, inhibited IFN-γ production by T cells but had little effect on the CTL activity of tumor specific CD8 T cells.
IL-17 is required for the development of myeloid derived suppressor cells
An increased number of myeloid derived suppressor cells (MDSC) in spleen, blood and tumors is a hallmark of major immunological abnormalities in cancer patients and tumor bearing animals (5–7). MDSC are considered as an immature form of myeloid cells which are mostly identified as CD11b and Gr-1 double positive cells in mice (7, 10). We found that the percent of CD11b/Gr-1 double positive MDSC in the spleen of IL-17R−/− tumor bearing mice was lower than that of wild type tumor bearing mice (Fig. 6a). The deficiency in IFN-γR had little effect on MDSC whereas MDSC in the double knockout mice that were deficient in both IL-17R and IFN-γR was reduced. Further analysis showed that MDSC in the spleen, blood and tumors of IL-17R−/− and the double knockout mice was significantly reduced compared to wild type controls (Fig. 6b).
In further experiments, results showed that spleens from tumor bearing mice that were treated with Ad-IL-17 (as described in Fig. 2a) contained a significantly higher level of MDSC than those from the mice that were treated with Ad-GFP or untreated control (Fig. 6c). In contrast, the number of MDSC in the spleen of tumor bearing mice which were treated with anti-IL-17 antibody (as described in Fig. 2b) was significantly reduced compared to controls that were treated with normal rat IgG (Fig. 6d). The deficiency in IFN-γR or IL-17R did not have a significant effect on the number of MDSC in tumor free naïve mice (data not shown).
IL-17 regulates the phenotype and function of myeloid derived suppressor cells
The tumor promoting function of MDSC is associated with increased activities of arginase-1 (Arg-1), MMP9, and S100A8/A9 (7, 10, 52). To examine mechanisms for IL-17 mediated effects on the phenotype of MDSC in tumor bearing mice, MDSC were purified from spleens of tumor bearing mice and stimulated with LPS in vitro for overnight. Our initial experiments showed a very low expression level of the molecules by freshly isolated MDSC without the LPS stimulation (data not shown). Results showed that MDSC from IL-17R−/− tumor bearing mice expressed lower levels of Arg-1, MMP9 and S100A8/A9 than those from wild type tumor bearing mice (Fig. 7). Furthermore, MDSC from Ad-IL-17 treated tumor bearing wild type mice expressed a higher level of the molecules than those from mice that were treated with Ad-GFP or left untreated (Fig. 7).
In experiments examining the tumor promoting function of MDSC, results showed that co-injection of MDSC purified from wild type E.G7-OVA tumor bearing mice significantly increased tumor growth whereas co-injection of MDSC from IL-17R−/− tumor bearing mice did not affect tumor growth compared to control mice that were not injected with MDSC (Fig. 8a). In contrast, MDSC from wild type tumor bearing mice that were treated with Ad-IL-17 promoted tumor growth to a significant greater extent than those from control wild type tumor bearing mice that were treated with Ad–GFP (Fig. 8b). Furthermore, similar results were also observed in mouse B16 melanoma model, which showed a reduced tumor promoting effect of MDSC from IL-17R−/− B16 tumor bearing mice compared to those from wild type counterparts (Fig. 8c). However, the tumor promoting activity of MDSC was dependent on the presence of tumors since co-injection of MDSC cells from naïve tumor free IL-17R−/− or wild type mice did not have a significant effect on tumor growth compared to control animals that were not injected with MDSC (Fig. 8d).
In experiments examining the immunosuppressive effect of MDSC, MDSC from wild type tumor bearing mice significantly inhibited the proliferation of CD4 T cells compared to control CD11b+ cells which were purified from tumor free mice (Fig. 8e). In contrast, MDSC from IL-17R−/− tumor bearing mice did not have an inhibitory effect on T cell proliferation compared to the control CD11b+ cells. These results indicate that MDSC from IL-17R−/− tumor bearing mice lack the functions in both tumor promotion and immunosuppression.
DISCUSSION
The role of IL-17 in the regulation of tumor immune responses has yet to be fully understood. In the current study, we have used IL-17R−/− and IL-17/IFN-γR double knockout mice to specifically examine the role of IL-17 mediated immune responses in tumor development. Results indicate that IL-17 promotes tumor growth whereas the blockade of IL-17R inhibits tumor growth and even reverses the susceptibility of IFN-γR−/− mice to tumor development. IL-17 inhibits the infiltration of CD8 T cells but increases the infiltration of MDSC in tumors, a characteristic of tumor promoting microenvironment at tumor sties. Furthermore, IL-17 is required for MDSC mediated tumor promoting activity but had little effect on the CTL activity of tumor specific CD8 T cells although a defect in IL-17R reduces IFN-γ production by T cells. These data demonstrate that IL-17 mediated responses, especially at tumor sites, promote tumor development and provide insights into novel mechanisms by which Th1 and Th17 responses regulate tumor immunity.
A line of evidence indicates that IL-17 has tumor promoting effects, especially in the context of inflammations (29, 53, 54). A recent report shows that the growth of tumors is inhibited in IL-17−/− and IFN-γ/IL-17 double knockout mice (31). However, conflict recent reports show that tumor growth is increased in IL-17−/− mice (32, 35). In the report by Wang et al, IL-17 induces IL-6 production by tumor cells and stromal cells that express IL-17R. IL-6 promotes tumor growth in a Stat-3 dependent pathway (31). In the report by Kryczek et al, IFN–γ producing NK and T cells are reduced, which is considered to be a mechanism for the increased tumor growth in IL-17−/− mice (32). Martin-Orozco et al showed that application of Th17 cells increased IFN-γ producing CD8 T cells in lungs with metastatic B16 tumors (35). Interestingly, Wang et al show that the infiltration of CD8 T cells in tumors and IFN-γ production by tumor infiltrating T cells are increased in IL-17−/− mice (31). The report by Wang et al (31) and our studies used the mouse melanoma cell line B16 and found similar results in IL-17−/− and IL-17R−/− mice whereas Kryczek et al used MC38 sarcoma and Martin-Orozco et al used B16 metastasis model (32, 35). It is possible that IL-17 may have different roles in different tumors and tumor models. Additionally, different mouse models (IL-17−/− vs. IL-17R−/−) may also contribute to the discrepancy. Notably, the studies reporting protective roles of IL-17 in tumor immunity imply that the stimulation of IFN-γ production by IL-17 is important for IL-17 mediated anti-tumor immunity and the reduction of IFN-γ production and IFN-γ producing cells is a primary mechanism for the deficient anti-tumor immunity in IL-17−/− mice (31, 35). Our results suggests that IFN-γ appears to play a minor role in IL-17 mediated regulation of tumor development since tumor growth is inhibited in the IL-17R/IFN-γR double knockout mice (Fig. 1d). This result is in consistent to Wang’s report showing that tumor growth is inhibited in IL-17/IFN-γ double knockout mice (31). Our studies implicate that IL-17 mediated tumor promotion is associated with the inhibition of CD8 T cell infiltration in tumors and enhancement of MDSC development and function. Importantly, the CTL activity of tumor specific CD8 T cells is not significantly affected by the IL-17R deficiency although IFN-γ production is inhibited (Fig. 5). The inhibition of MDSC is a critical mechanism for the suppression of tumor growth in IL-17R−/− and IL-17R/IFN-γR double knockout mice. Certainly, additional studies are required to further determine why IL-17 has different effects on modulating tumor development in different tumor models. An important issue is the effect of IL-17 responses on the function of tumor infiltrating CD4 and CD8 T cells, which is under our on-going studies.
MDSC are considered as an immature form of myeloid cells, which are present in the blood, spleen and bone marrow of normal mice and are increased in infectious diseases and tumors (5–8, 10). MDSC play important roles in the suppression of immune responses and promotion of tumor growth (5, 6, 8). Although IL-17 production is increased in inflammatory reactions and considered as an inflammatory cytokine promoting tumor development (29, 53, 54), it was not known whether IL-17 had an effect on MDSC in tumor bearing hosts. Our studies have implicated that IL-17 is required for the development of MDSC in tumor bearing mice. A defect in IL-17R reduces the number of MDSC in the blood, spleen and tumors. This is further supported by our data showing that the administration of exogenous IL-17 increases the number of MDSC in wild type tumor bearing mice whereas neutralization of IL-17 in wild type tumor bearing mice reduced the number of MDSC. It will be very interesting to examine whether IL-23 mediated promotion of tumor development, which is associated with an increased level of IL-17 and myeloid cell infiltration in tumors (29), is linked to IL-17 mediated regulation of MDSC.
MDSC inhibit immune responses and promote tumor growth by complexes of mechanisms (6, 55). We show that MDSC from wild type tumor bearing mice exhibit high levels of Arg-I, A100/A8/A9 and MMP9 molecules which are known to be mediators for MDSC mediated immunosuppression and tumor promotion (5, 7, 8, 52). However, MDSC from IL-17R−/− tumor bearing mice express a low level of the molecules, which is almost comparable to that of MDSC from tumor free naïve mice. Accordingly, co-application of MDSC from IL-17R−/− tumor bearing mice does not have a significant effect on tumor growth. In contrast, the treatment with exogenous IL-17 increases the expression level of the molecules and enhances the tumor promoting activity of MDSC. Furthermore, MDSC from IL-17R−/− tumor bearing mice do not have a significant immunosuppressive effect on T cell activation compared to the wild type counterparts. These data demonstrate that IL-17 signals are required not only for the development but also for the tumor promoting and immunosuppressive activity of MDSC.
Heavy infiltration of MDSC has been considered as a major cause for immunosuppression at tumor sites (5, 8, 9). The infiltration of immune T cells in tumors is associated with good prognosis (45) whereas infiltration of MDSC is associated with poor prognosis (5, 8). Our data show that although IL-17 does not have inhibitory effects on tumor specific T cells or even stimulates IFN-γ production by T cells, its opposite effects on the infiltration of CD8 T cells and MDSC in tumors imply an important mechanism for IL-17 mediated tumor promoting microenvironments at tumor sites. This is supported by our data showing that proliferation is inhibited whereas apoptosis is increased in the tumors of IL-17R−/− mice (Fig. 3). It is to note that the tumor growth is increased whereas the number of MDSC is not significantly affected in IFN-γR−/− mice. Since IFN-γ signals are known to have antitumor activities (36–38), the deficiency in IFN-γ mediated anti-tumor immunity may lead to the increased tumor growth. However, the reduction of MDSC provides an interpretation for the suppression of E.G7-OVA tumor growth in IL-17R/IFN-γR−/− compared IFN-γR−/− mice. A recent report shows that MDSC are able to inhibit the migration of T cells by down regulating the expression of L-selectin by T cells (56). Further experiments are required to determine whether IL-17 mediated opposite effects on CD8 and MDSC infiltration is dependent on the interaction of MDSC with CD8 T cells or the induction of specific chemokines for the cells.
In summary, our studies have demonstrated that IL-17 promotes tumor growth. Moreover, a defect in IL-17 mediated responses can reverse the susceptibility to tumor development in mice which are deficient in IFN-γ mediated anti-tumor responses. IL-17 induces tumor promoting microenvironments at tumor sites and its effects on MDSC represent an important mechanism for the tumor promoting effect. Our studies provide insights into novel mechanisms by which IL-17 mediates tumor promoting immune responses at tumor sites. Targeting IL-17 may be developed to new immunotherapeutic strategies for treatment of tumors.
Acknowledgments
We thank Dr. Dr. Jay K. Kolls for providing adenovirus encoding mouse IL-17 and Dr. Hui-Chen Hsu for helpful discussions about experiments.
Abstract
The role of immune responses in tumor development is a central issue for tumor biology and immunology. IL-17 is an important cytokine for inflammatory and autoimmune diseases. Although IL-17 producing cells are detected in cancer patients and tumor bearing mice, the role of IL-17 in tumor development is controversial and mechanisms remain to be fully elucidated. In the current study, we found that the development of tumors was inhibited in IL-17 receptor A (IL-17R) deficient mice. A defect in IFN-γ receptor increased tumor growth whereas tumor growth was inhibited in mice that were deficient in both IL-17R and IFN-γR compared to wild type animals. Further experiments showed that neutralization of IL-17 by antibodies inhibited tumor growth in wild type mice whereas systemic administration of IL-17 promoted tumor growth. The IL-17R deficiency increased CD8 T cell infiltration whereas it reduced the infiltration of myeloid derived suppressor cells (MDSC) in tumors. In contrast, administration of IL-17 inhibited CD8 T cell infiltration and increased MDSC in tumors. Further analysis indicated that IL-17 was required for the development and tumor promoting activity of MDSC in tumor bearing mice. These data demonstrate that IL-17 mediated responses promote tumor development through the induction of tumor promoting microenvironments at tumor sites. IL-17 mediated regulation of MDSC is a primary mechanism for its tumor promoting effects. The study provides novel insights into the role of IL-17 in tumor development and has major implications for targeting IL-17 in treatment of tumors.
Abbreviations
MDSC | myeloid derived suppressor cells |
BM-DC | Bone marrow derived dendritic cells |
Footnotes
This publication was made possible by AR46256 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and AI071041 from the National Institute of Allergy and Infectious Diseases (H.X). This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant No. C06 RR 15490 from the National Center for Research Resources, National Institutes of Health.
DISCLOSURES
All authors concur with the submission and have no financial conflict of interest.
REFERENCE
References
- 1. Vakkila J, Lotze MTInflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641–648.[PubMed][Google Scholar]
- 2. de Visser KE, Eichten A, Coussens LMParadoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37.[PubMed][Google Scholar]
- 3. Balkwill F, Charles KA, Mantovani ASmoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217.[PubMed][Google Scholar]
- 4. Clevers HAt the Crossroads of Inflammation and Cancer. Cell. 2004;118:671–674.[PubMed][Google Scholar]
- 5. Gabrilovich DI, Nagaraj SMyeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–174.[Google Scholar]
- 6. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte VTumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews. 2008;222:162–179.[PubMed][Google Scholar]
- 7. Serafini P, Borrello I, Bronte VMyeloid suppressor cells in cancer: Recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology. 2006;16:53–65.[PubMed][Google Scholar]
- 8. Ostrand-Rosenberg S, Sinha PMyeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. J Immunol. 2009;182:4499–4506.[Google Scholar]
- 9. Nagaraj S, Gabrilovich DITumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells. Cancer Res. 2008;68:2561–2563.[PubMed][Google Scholar]
- 10. Bronte V, Zanovello PRegulation of immune responses by L-arginine metabolism. Nat Rev Immunol. 2005;5:641–654.[PubMed][Google Scholar]
- 11. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JAIdentification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008;111:4233–4244.[PubMed][Google Scholar]
- 12. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DISubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice. J Immunol. 2008;181:5791–5802.[Google Scholar]
- 13. Weaver CT, Hatton RD, Mangan PR, Harrington LEIL-17 Family Cytokines and the Expanding Diversity of Effector T Cell Lineages. Annual Review of Immunology. 2007;25:821–852.[PubMed][Google Scholar]
- 14. Gaffen SLStructure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–567.[Google Scholar]
- 15. Kolls JK, Linden AInterleukin-17 family members and inflammation. Immunity. 2004;21:467–476.[PubMed][Google Scholar]
- 16. Dong CDiversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006;6:329–334.[PubMed][Google Scholar]
- 17. He D, Wu L, Kim HK, Li H, Elmets CA, Xu HCD8+ IL-17-Producing T Cells Are Important in Effector Functions for the Elicitation of Contact Hypersensitivity Responses. J Immunol. 2006;177:6852–6858.[Google Scholar]
- 18. Kelly MN, Kolls JK, Happel K, Schwartzman JD, Schwarzenberger P, Combe C, Moretto M, Khan IAInterleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun. 2005;73:617–621.[Google Scholar]
- 19. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JKRequirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194:519–527.[Google Scholar]
- 20. Kolls JK, Linden AInterleukin-17 Family Members and Inflammation. Immunity. 2004;21:467–476.[PubMed][Google Scholar]
- 21. Koenders MI, Kolls JK, Oppers-Walgreen B, van den Bersselaar L, Joosten LA, Schurr JR, Schwarzenberger P, van den Berg WB, Lubberts EInterleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 2005;52:3239–3247.[PubMed][Google Scholar]
- 22. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki HIL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis. J Immunol. 2005;175:6177–6189.[PubMed][Google Scholar]
- 23. He D, Wu L, Kim HK, Li H, Elmets CA, Xu HIL-17 and IFN-{gamma} Mediate the Elicitation of Contact Hypersensitivity Responses by Different Mechanisms and Both Are Required for Optimal Responses. J Immunol. 2009;183:1463–1470.[Google Scholar]
- 24. McGeachy MJ, Cua DJTh17 Cell Differentiation: The Long and Winding Road. Immunity. 2008;28:445–453.[PubMed][Google Scholar]
- 25. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, Chang A, Zou WCutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. J Immunol. 2007;178:6730–6733.[PubMed][Google Scholar]
- 26. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, Yang YA, Laurence A, Michalowska A, Mamura M, Lonning S, Berzofsky JA, Wakefield LMTransforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Research. 2008;68:3915–3923.[Google Scholar]
- 27. Miyahara Y, Odunsi K, Chen W, Peng G, Matsuzaki J, Wang R-FGeneration and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proceedings of the National Academy of Sciences. 2008;105:15505–15510.[Google Scholar]
- 28. Yusuf N, Nasti TH, Katiyar SK, Jacobs MK, Seibert MD, Ginsburg AC, Timares L, Xu H, Elmets CAAntagonistic Roles of CD4+ and CD8+ T-Cells in 7,12-Dimethylbenz(a)anthracene Cutaneous Carcinogenesis. Cancer Res. 2008;68:3924–3930.[Google Scholar]
- 29. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft MIL-23 promotes tumour incidence and growth. Nature. 2006;442:461.[PubMed][Google Scholar]
- 30. Honorati MC, Neri S, Cattini L, Facchini AIL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol. 2003;133:344–349.[Google Scholar]
- 31. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu HIL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009;206:1457–1464.[Google Scholar]
- 32. Kryczek I, Wei S, Szeliga W, Vatan L, Zou WEndogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114:357–359.[Google Scholar]
- 33. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan C-C, Restifo NPTumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–373.[Google Scholar]
- 34. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NPType 17 CD8+ T cells display enhanced anti-tumor immunity. Blood. 2009 blood-2009-2002-203935. [Google Scholar]
- 35. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong CT Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity. 2009;31:787.[Google Scholar]
- 36. Dunn GP, Koebel CM, Schreiber RDInterferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836.[PubMed][Google Scholar]
- 37. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini AInterleukin-12: Biological Properties and Clinical Application. Clin Cancer Res. 2007;13:4677–4685.[PubMed][Google Scholar]
- 38. Trinchieri GInterleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133.[PubMed][Google Scholar]
- 39. Frey AB, Monu NEffector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol. 2006;79:652–662.[PubMed][Google Scholar]
- 40. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin HImmune resistance orchestrated by the tumor microenvironment. Immunological Reviews. 2006;213:131–145.[PubMed][Google Scholar]
- 41. Whiteside TLThe tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912.[Google Scholar]
- 42. Wang HY, Wang R-FRegulatory T cells and cancer. Current Opinion in Immunology. 2007;19:217–223.[PubMed][Google Scholar]
- 43. Joyce JA, Pollard JWMicroenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239–252.[Google Scholar]
- 44. Zou WRegulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.[PubMed][Google Scholar]
- 45. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Pages FType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science. 2006;313:1960–1964.[PubMed][Google Scholar]
- 46. Kim HK, Zhang H, Li H, Wu ZT, Swisher S, He D, Wu L, Xu J, Elmets CA, Athar M, Xu XC, Xu HSlit2 Inhibits Growth and Metastasis of Fibrosarcoma and Squamous Cell Carcinoma. Neoplasia. 2008;10:1411–1420.[Google Scholar]
- 47. Hsu H-C, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le T-vL, Lorenz RG, Xu H, Kolls JK, Carter RH, Chaplin DD, Williams RW, Mountz JDInterleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008;9:166–175.[PubMed][Google Scholar]
- 48. Kapp JA, Honjo K, Kapp LM, Xu Xy, Cozier A, Bucy RPTCR transgenic CD8+ T cells activated in the presence of TGF{beta} express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int. Immunol. 2006;18:1549–1562.[PubMed][Google Scholar]
- 49. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura YAntigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17:375–387.[PubMed][Google Scholar]
- 50. Bettelli E, Oukka M, Kuchroo VKTH-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8:345–350.[PubMed][Google Scholar]
- 51. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, Shellito JE, Bagby GJ, Nelson S, Charrier K, Peschon JJ, Kolls JKRequirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. Journal of Experimental Medicine. 2001;194:519.[Google Scholar]
- 52. Gebhardt C, Németh J, Angel P, Hess JS100A8 and S100A9 in inflammation and cancer. Biochemical Pharmacology. 2006;72:1622–1631.[PubMed][Google Scholar]
- 53. Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, Balkwill FR, Hagemann TThe tumor-promoting actions of TNF-a involve TNFR1 and IL-17 in ovarian cancer in mice and humans. The Journal of Clinical Investigation. 2009;119:3011.[Google Scholar]
- 54. Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F, Housseau F, Pardoll DM, Sears CLA human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15:1016.[Google Scholar]
- 55. Allavena P, Sica A, Solinas G, Porta C, Mantovani AThe inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Critical Reviews in Oncology/Hematology. 2008;66:1–9.[PubMed][Google Scholar]
- 56. Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg SMyeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells. J Immunol. 2009;183:937–944.[Google Scholar]